Verified Nov 2026
Other
·
Vienna, Vienna
·
Since
Janssen-Cilag Pharma GmbH, headquartered in Vienna, Austria, is a pharmaceutical division of Johnson & Johnson with 10,000–50,000 employees and over $10 billion in revenue. The company develops medicines across oncology, immunology, neuroscience, cardiovascular and metabolism, pulmonary hypertension, and retina therapies. In 2026, the company secured pharmaceutical supply contracts with Spanish health authorities.
Janssen-Cilag Pharma GmbH at a glance
Revenue
$10B+
Est. band
Employees
10,000-50,000
Headquarters
Vienna, Vienna
Certifications
ISO 9001
Industries
Automotive
Electric Vehicles
Medical
Overview
Janssen-Cilag Pharma GmbH, headquartered in Vienna, Austria, is a pharmaceutical division of Johnson & Johnson with 10,000–50,000 employees and over $10 billion in revenue. The company develops medicines across oncology, immunology, neuroscience, cardiovascular and metabolism, pulmonary hypertension, and retina therapies. In 2026, the company secured pharmaceutical supply contracts with Spanish health authorities.
At a glance
Attribute | Detail |
|---|---|
Headquarters | Vienna, Vienna |
Employees | 10,000-50,000 |
Revenue | $10B+ (estimated) |
Certifications | ISO 9001 |
What Janssen-Cilag Pharma GmbH makes
Janssen-Cilag holds ISO 9001 certification and develops marketed medicines including DARZALEX FASPRO®, RYBREVANT FASPRO™, and CAPLYTA® across multiple therapeutic areas.
Certifications
Janssen-Cilag Pharma GmbH is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 9001 — jnj.com
Latest developments
2026-10-07 — Pharmaceutical products contract award in Spain: CBAM 578/2025 JANSSEN/01 | 692215-2026 (initask.com)
2026-09-03 — Pharmaceutical products contract award in Spain: Acuerdo Marco para el suministro de medicamentos… | 607614-2026 (initask.com)
2026-02-07 — Minister Jo Brouns verleent nieuwe omgevingsvergunning voor Janssen Pharmaceutica in Beerse: “Belangrijk om strategisch bedrijf in Vlaanderen te verankeren” — Jo Brouns (jobrouns.be)
2025-06-03 — MGI Pharma licenses Dacogen to J&J for non-North America development, commercialization. (ainvest.com)
Company details
As part of Johnson & Johnson, the company operates in automotive, electric-vehicle, and medical sectors with a workforce spanning 10,000–50,000 employees. Janssen-Cilag Pharma GmbH has an estimated 10,000-50,000 employees, and is headquartered in Vienna, Vienna.
Frequently asked questions
What does Janssen-Cilag Pharma GmbH do?
Janssen-Cilag Pharma GmbH, headquartered in Vienna, Austria, is a pharmaceutical division of Johnson & Johnson with 10,000–50,000 employees and over $10 billion in revenue. The company develops medicines across oncology, immunology, neuroscience, cardiovascular and metabolism, pulmonary hypertension, and retina therapies. In 2026, the company secured pharmaceutical supply contracts with Spanish health authorities.
Where is Janssen-Cilag Pharma GmbH headquartered?
Janssen-Cilag Pharma GmbH is headquartered in Vienna, Vienna.
How big is Janssen-Cilag Pharma GmbH?
Janssen-Cilag Pharma GmbH has an estimated 10,000-50,000 employees, with revenue in the $10B+ range (estimated).
What certifications does Janssen-Cilag Pharma GmbH hold?
Janssen-Cilag Pharma GmbH lists ISO 9001 on its website. Confirm the certified scope for the specific plant producing your part.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
